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membranes obtained from supplemented mice. To deter-
mine whether a milk CLA-enriched diet possesses allergo-
protective properties, female Balb/c mice were fed the milk 
CLA-enriched diet ahead of sensitization and a challenge 
with ovalbumin (OVA) and the parameters of airway inflam-
mation and eisosanoid pattern were measured.  Results: In 
animals, supplementation with a diet rich in milk CLA result-
ed in elevated CLA levels in plasma and erythrocyte mem-
branes, indicating bioavailability of milk fatty acids. Though 
membrane-associated phospholipid patterns were affected 
by supplementation with milk CLA, this application neither 
reduced the hallmarks of allergic airway inflammation in sen-
sitized and OVA-challenged mice nor modified the eicon-
sanoid pattern in the bronchoalveolar lavage fluid of these 
animals.  Conclusion: Milk-associated CLA was not capable of 
preventing murine allergic airway inflammation in an animal 
model of OVA-induced allergic airway inflammation. 
 © 2014 S. Karger AG, Basel 
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 Abstract 
 Background: Cross-sectional epidemiological studies have 
demonstrated that farm milk from traditional farm settings 
possesses allergoprotective properties. Up to now, it has not 
been clarified which milk ingredient is responsible for pro-
tection against allergic diseases. As farm milk is rich in con-
jugated linoleic acids (CLA), it is hypothesized that this n–3 
polyunsaturated fatty acid family contributes to the allergo-
protective capacity of farm milk. We aim to prove this hy-
pothesis in a murine model of allergic airway inflammation. 
 Methods: To prove the bioavailability and allergoprotective 
capacity of milk-associated CLA in a standardized protocol, 
milk batches that differed significantly in terms of their CLA 
content were spray dried and incorporated into a basic diet 
by substituting the regular sunflower fat fraction. Initially, 
the milk CLA uptake from the diet was monitored via mea-
surement of the CLA content in plasma and erythrocyte 
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 In many regions of the world, cow’s milk consumption 
has been a common part of the human diet for more than 
7,000 years since ancient farmers developed dairy culture 
 [1] . In industrialized countries, the traditional pasture 
husbandry system was progressively forced back during 
the last century in favor of intensive indoor keeping and 
feeding of livestock. However, in some alpine farm set-
tings, traditional production of cow’s milk is still com-
mon and there is growing evidence that early and con-
tinuing consumption of such ‘farm milk’ acts protective-
ly against atopy and allergic diseases  [2, 3] . A number of 
potential explanations for the beneficial effect of tradi-
tionally produced cow’s milk on allergies have been dis-
cussed, but to date no profound proof of concept is avail-
able  [4, 5] . However, epidemiological evidence has point-
ed to lipid components as putative factors which might 
prevent allergies. Two studies independently demon-
strated that an intake of dairy products with a high amount 
of milk fat was associated with a reduced risk of asthma 
development  [6, 7] . Controversially, there are recent 
studies demonstrating the opposite effect  [8, 9] .
 Cow’s milk lipids represent important nutritional 
sources for n–3 poly-unsaturated fatty acids (n3-PUFA), 
a family of fatty acids (FA) which has been discussed as 
a protective factor in chronic airway inflammatory con-
ditions  [10] . In this context, it was recently shown that, 
in comparison to milk from indoor-fed animals, cow’s 
milk from pastured animals kept on traditionally run al-
pine farms is rich in ruminant milk lipids of the n3- PUFA 
family. Among them, conjugated linoleic acids (CLA) 
were found to be most dominantly elevated in milk from 
pastured cows  [11–13] . CLA were shown to possess 
strong immunomodulatory properties  [14] and this led 
us to hypothesize that CLA might contribute to the al-
lergoprotective effects of farm milk.  c9,t11 -CLA, the 
most abundant CLA in dairy products, has been previ-
ously shown to antagonize the production of inflamma-
tory mediators by inhibiting the sequential steps of pros-
taglandin (PG) and thromboxane (TX) synthesis  [15] . 
These mediators play a major role in the establishment 
of inflammatory conditions involved in the pathology of 
asthma. A first clinical study in mild asthmatics on a diet 
supplemented with CLA strengthened the assumption 
that CLA might contribute to protection against airway 
inflammation in the context of allergic asthma  [16] . An-
other placebo-controlled study conducted in allergic pa-
tients revealed that oral CLA supplementation improved 
symptoms and immunological parameters during pollen 
season  [17] . In line with these findings an experimental 
approach in a murine model of asthma where mice were 
fed a synthetically produced CLA derivate underlined 
that dietary CLA uptake might lead to allergoprotection 
 [18] .
 However, the concept that cow’s milk, which is rich in 
CLA, is capable of having preventive effects on allergic 
airway inflammation and thereby may contribute to the 
effects of farm milk has not yet been proven using an ex-
perimental approach. Here, we aim to determine whether 
CLA-rich farm-collected milk (directly collected on 
farms) is able to prevent asthma in a well-established mu-
rine in vivo model of acute airway inflammation. In ac-
cordance with Kanwar et al.  [19] , we incorporated spray 
dried milk prepared from freshly collected and subse-
quently pasteurized milk batches into the mouse diet to 
standardize milk supplementation. To determine wheth-
er alteration of the asthmatic phenotype is a function of 
the CLA content, we supplied diets with high and low 
milk-associated CLA contents.
 Methods 
 Milk Collection and Preparation of Milk Fat Diets with 
Different CLA Contents 
 Prior to the proof-of-concept experiments, milk batches that 
differed significantly in terms of their CLA content were prepared. 
Based on recent data  [9, 10] , fresh milk was sampled on tradition-
ally run farms in Bavaria and on conventionally run farms in Hes-
sen to obtain high-CLA and low-CLA milk batches. As batches 
differed significantly in terms of their CLA content (online suppl. 
fig S1; for all online suppl. material, see www.karger.com/
doi/10.1159/000358523), they were immediately centrifuged and 
pasteurized at 72–73  °  C for 15 s after collection to exclude side ef-
fects of microbial contamination in later experiments. Measure-
ment of the CLA content of the freshly collected milk batches re-
vealed significant differences. In absolute numbers, the high-CLA 
milk contained 208 μg CLA/ml of milk, while the low-CLA milk 
contained 130 μg CLA/ml of milk. The integration of spray-dried 
milk had no influence on this ratio ( fig. 1 ). To ensure a standard-
ized uptake of milk FA by mice, pasteurized milk batches were 
spray dried and subsequently integrated into a basic diet formula-
tion substituting the original sunflower fat fraction with milk 
powder (online suppl. fig. S2). The high-CLA diet contained 
1.70%  cis- 9,  trans- 11 CLA and 0.10%  trans- 10,  cis- 12 CLA and the 
low-CLA diet contained 1.08%  cis- 9,  trans- 11 CLA and 0.04% 
trans- 10,  cis- 12 CLA, whereas the control diet (C1000) did not 
contain any CLA isomers. In the diets, the absolute CLA amounts 
reflected the ratio found in milk batches (53 μg/g diet vs. 38 μg/g 
diet). The estimated average daily uptake of CLA per gram of body 
weight was 12.54 μg for mice fed the high-CLA diet and 9.12 μg 
for mice fed the low-CLA diet, respectively. Control groups re-





















   
   
   
   
   
   
   
   
   
   
   


























 Six- to 8-week-old female Balb/c mice were obtained from 
 Harlan Winkelmann (Borchen, Germany). The mice were kept 
under specific pathogen-free housing conditions and were pro-
vided water and an ovalbumin (OVA)-free diet ad libitum. All ex-
periments were performed in accordance with German and inter-
national guidelines and were approved by local authorities.
 Sensitization, Challenge, and Feeding of Mice 
 In accordance with Conrad et al.  [20] , the mice were sensitized 
to OVA on days 0, 7, and 14 via subcutaneous injection (s.c.) of 10 
μg OVA (grade VI; Sigma, Steinheim, Germany) in 200 μl PBS. 
Sham-treated groups received 200 μl PBS. On days 26, 27, and 28, 
the animals were exposed to aerosolized OVA (1% weight/volume 
in PBS) for 20 min. Lung function was analyzed 24 h after the last 
aerosol challenge, and another 24 h later the mice were terminally 
anesthetized with ketamine plus Rompun ® for further analyses 
( fig. 1 ).
 Assessment of Airway Reactivity 
 Twenty-four hours after the last aerosol challenge, lung func-
tion analysis was performed using noninvasive head-out body 
plethysmography. Airway hyperresponsiveness, measured as de-
scribed previously  [21] , is represented in fig. 3 by a lower meta-
choline concentration that induced a 50% reduction of the baseline 
EF MCh50 .
 A principal comparison of noninvasive head-out body plethys-
mography with invasive Flexivent lung function analysis in our 
laboratory revealed concordance (data not shown).
 BAL and Differential Cell Count 
 Using a tracheal cannula, BAL was performed using 1 ml PBS 
containing a protease inhibitor cocktail (Roche). An automated 
 CasyTT cell counter (Schaerfe Systems, Reutlingen, Germany) was 
used to determine total leukocyte cell counts. For differential cell 
count analysis, cytospin preparations were prepared, fixed, and 
stained with Diff-Quick (Merz & Dade AG, Dudingen, Switzerland) 
and standard morphological criteria were used to identify cell types.
 Restimulation of Lymph Node Cells 
 Single cell suspensions of mediastinal lymph node cells were 
generated by filtering lymph nodes through a 100-μm cell strainer, 
washing and resuspending the cells in RPMI medium with 10% 
FCS. After counting, the lymph node cells were seeded at 2 × 10 6 /
ml in 96 wells and incubated with or without OVA (25 μg/ml) for 
72 h at 37   °   C. Cell-free supernatants were collected and stored at 
–20  °  C until cytokine measurement.
 Measurement of Cytokines 
 Cell-free supernatants were analyzed for interleukin (IL)-4, IL-
5, IL-10, and IFN-γ using a cytometric bead array (CBA; BD Sci-
ence, San Diego, Calif., USA). The assay was performed as recom-
mended by the manufacturer.
 Measurement of Serum Antibodies 
 Blood samples were taken from the axillary vessels, and serum 
levels of anti-OVA IgE, anti-OVA IgG1, and anti-OVA IgG2a were 
measured by ELISA as previously described  [22] .
 Quantitative Morphological Analysis of Mucin Production 
 Directly after BAL, the lungs were fixed with 6% paraformalde-
hyde. Lung tissues were embedded into paraffin, and 3-μm sec-
tions were stained with periodic acid-Schiff. Goblet cell metaplasia 
and the volume of epithelial mucin per surface area of airway bas-
al membrane were determined using the computer-assisted stere-
ology tool box (CAST Grid 2.0; Olympus) as described previously 
by Conrad et al.  [23] .
 Assessment of FAs in Milk, Serum, and Erythrocyte 
Membranes 
 Blood samples were taken and a panel of different FAs in serum 
and erythrocyte membranes was assessed as described by Böcking 
et al.  [24] .
 Phospholipid Analysis in Erythrocyte Membranes 
 The lipid extracts (150 μl) in hexane were evaporated and the 
residue was redissolved in 200 μl chloroform/methanol = 83/13. 
Twenty-five microliters of the reconstituted lipid extracts were 
mixed with 25 μl of a mixture of  2 H internal standards (one per 
lipid class of interest at 1.43 ng/μl, each in chloroform). Samples 
were separated by head groups using normal-phase HPLC. The 
solvents, gradient profiles, and flow rates are summarized in online 
supplementary table S1. Online detection was performed using a 
high-resolution hybrid Apex-Qe FT-MS system (Bruker Dalton-
ics, Bremen, Germany) equipped with a 7-tesla actively shielded 
superconducting magnet and an Apollo Dual ESI/MALDI ion 
source. Mass spectra were summed according to the respective Rf 
values of the lipid groups of interest and analyzed using LipID  [25] , 
allowing verification of the head groups and the overall FA com-
position including the degree of saturation. As based on the exact 
mass only the total number of carbon atoms and double bonds in 
both FA chains can be determined, MS/MS was applied to identify 








Basic diet (C1000)Milk diet Fig. 1. Protocol of the acute murine model 
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 Measurement of Eicosanoids in BAL 
 The amounts of PG D 2 (PGD 2 ), E 2 (PGE 2 ), F 2a (PDF 2a ), and 
6-keto-PGF 1a , as well as TXB 2 , leukotriene (LT) B 4 (LTB 4 ), 5S-
HETE, and 15S-HETE in bronchoalveolar lavage (BAL) fluid were 
determined by LC-MS/MS as described by Schmidt et al.  [26] and 
Maier et al.  [27] using an API 4000 triple quadrupole mass spec-
trometer (Applied Biosystems, Darmstadt, Germany).
 Statistical Analyses 
 Data analyses of animal experiments were performed using 
GraphPad Prism ® (GraphPad Software Inc., La Jolla, Calif., USA). 
All numerical data are expressed as means ± SEM and were ana-
lyzed for significance using one-way ANOVA and Tukey tests. p < 
0.05 was considered statistically significant.
 Results 
 Milk Fat CLA Are Bioavailable after Feeding 
 Prior to the proof-of-concept experiments, we investi-
gated the bioavailability of milk-derived CLA incorpo-
rated into the diet. For this purpose, 6-week-old female 
Balb/c mice were fed a high-CLA, low-CLA, or control 
diet (C1000) for 21 days and the kinetics of the CLA up-
take in plasma and erythrocyte membranes were moni-
tored in each group. Blood was taken from the mice of 
each group (n = 4) on days 0, 7, 14, and 21. Determination 
of CLA levels in plasma and erythrocyte membranes 
showed an increasing presence of the CLA isomers  cis9, 
trans11 -CLA and  trans10, cis12 -CLA over time in milk 
diet-fed mice (high-CLA and low-CLA diets) compared 
to controls. However, this increase only reached statisti-
cal significance for C18: 2 t10,c12 in the erythrocyte mem-
branes of mice fed the high-CLA-diet ( fig. 2 ).
 A Diet Rich in Milk CLA Does Not Affect Allergic 
Sensitization and Airway Inflammation in Mice 
 To analyze whether milk CLA-enriched diets may pre-
vent the development of allergic airway inflammation, we 
employed a well-established acute model of murine exper-
imental asthma based on s.c. sensitization with OVA  [20] . 
Six-week-old female Balb/c mice were fed high-CLA and 
0





















































 Fig. 2. Kinetics of CLA uptake into plasma and erythrocyte mem-
branes. Female Balb/c mice (n = 4 per group) were fed a basic diet 
(C1000), a high-CLA, and and low-CLA diet, respectively, ad libi-
tum. The FA composition in plasma and erythrocytes was deter-
mined on a weekly basis by gas chromatography. C18: 2 c9,t11 ( a ) 
and C18: 2 t10,c12 ( b ) in plasma and C18: 2 c9,t11 ( c ) and C18: 2 
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low-CLA milk diets prior to sensitization, while control 
animals received a milk-free control diet (C1000). To estab-
lish a preventive condition, mice were fed the CLA-en-
riched diet for 4 weeks prior to sensitization and aerosol 
challenge. To determine whether allergic sensitization was 
affected by consumption of CLA-containing diets, we as-
sessed the OVA-specific IgE, IgG 1 , and IgG 2a production in 
serum. No significant changes were observed in the milk-
fed OVA-sensitized/challenged groups compared to the sh-
am-treated OVA-sensitized/challenged group ( fig. 3 a). 
 Further, we analyzed differential cell counts in the 















































































































































PBS/PBS + CLA-free diet
OVA/OVA + CLA-free diet
OVA/OVA + high-CLA diet
OVA/OVA + low-CLA diet
 Fig. 3. Effects of a milk CLA-enriched diet on the hallmarks of 
acute airway inflammation in Balb/c mice subjected to an OVA 
(s.c.)-induced model of experimental asthma.  a OVA-specific an-
tibody levels in serum.  b Differential eosinophil cell counts in BAL 
fluids.  c Number of mucus-producing goblet cells and mucus vol-
ume (V GC ) quantified by the CAST system in periodic acid-Schiff-
stained histologic lung sections.  d In vitro cytokine production of 
OVA-restimulated lymph node cells (72 h), measured with ELISA. 
 e Airway hyperresponsiveness to metacholine (MCh 50 )  measured 
by head-out body plethysmography (n = 8). Given is the meta-
choline concentration that induced a 50% reduction of the baseline 
EF MCh50 . Statistical testing was carried out using a one-way 
 ANOVA with Tukey test analysis in relation to the non-CLA 
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not shown) nor eosinophils showed any significant dif-
ference between milk diet-fed and control diet-fed mice 
( fig. 3 b). Quantification of mucus-producing goblet cells 
and mucus volume in the different experimental groups 
showed an increased number of goblet cells and aug-
mented mucus production in OVA-sensitized/chal-
lenged mice. Animals fed the high-CLA diet or the low-
CLA diet did not show a reduction of goblet cell numbers 
and mucus production ( fig. 3 c).
 The assessment of T H 1/T H 2 cytokine profiles in OVA-
restimulated mediastinal lymph node cells showed no 
significant differences in milk diet-fed and OVA-sensi-
tized/challenged animals compared to OVA-sensitized/
challenged animals fed the CLA-free control diet ( fig. 3 d).
 Additionally, we did not observe any improvement of 
lung function in milk diet-fed mice compared to controls 
( fig. 3 e).
 Milk CLA Supplementation Did Not Alter the CLA 
Distribution in Erythrocyte PC and PE 
 Next, we analyzed the distribution of linoleic acid iso-
mers in erythrocyte PC and PE as these phospholipid sub-
types are substrates for phospholipase A2 generating free 
FAs (FFA) as major players in the eicosanoid-mediated 
initiation of inflammation  [28, 29] . Therefore, erythro-
cyte membranes were prepared from blood samples taken 
on day 28. Linoleic acid residues were found in PE 34: 2, 
PE 38: 6, and PE 36: 2 and in PC 34: 2, PC 36: 3, and PC 36: 
 2. Though we found differences in CLA content in the 
erythrocyte membranes after feeding with the milk CLA-
enriched diets compared to the control diet, we did not 
observe any changes in the phospholipids of the erythro-
cyte membranes ( table 1 ).
 Milk CLA-Enriched Diets Do Not Alter the Local 
Eicosanoid Release 
 Several in vivo  studies have proposed an influence of 
CLA on the production of eicosanoids by inhibiting the 
activity of enzymes such as carboxygenase and lipoxygen-
ase or competing with other FAs as a substrate for eico-
sanoid synthesis  [30–32] . The lipid mediators PGD 2 and 
LTB 4 are involved in the asthma pathogenesis  [33] . In or-
der to investigate whether consumption of CLA and their 
uptake into cell membranes alter the release of eicosanoid 
patterns, we determined the concentrations of PGD 2 , E 2 , 
F 2a , and 6-keto-PGF 1a as well as TXB 2 , LTB 4 , and 5S- and 
15S-HETE by LC-MS/MS.
 The lipid mediators PDF 2a , TXB 2 , and 5S- or 15S-
HETE were not detectable in the BAL fluid, whereas the 
asthma-relevant eicosanoid PGD 2 and LTB 4 and also 
PGE 2 and 6-keto-PDF 1a were found in the BAL fluid in 
each of the sensitized groups ( fig. 4 ). Nonetheless, analy-
ses did not reveal any significant changes in the concen-
tration of these lipid mediators between the control group 
and the experimental groups.
 Discussion 
 Findings from the ALEX study suggest that farm milk 
from traditional farm settings might contribute indepen-
dently of other farm exposures to the allergoprotective 
farm effect  [2] . So far, it has been a matter of speculation 
which farm milk ingredients might be responsible for this 
effect. Cow’s milk is a heterogenic product that varies 
broadly in its biochemical and microbial composition de-
pending on the region of origin and the husbandry condi-
tions on the farms  [34] . Our data indicate that the CLA 
content might be a marker for farm milk sampled from 
cows traditionally kept in the alpine region as this milk 
batch was characterized by a significantly elevated CLA 
level in comparison to milk sampled on conventionally 
run farms located elsewhere. These results are in line with 
former studies on CLA content in cow’s milk samples 
from the alpine region in comparison to other origins  [11, 
12] .
 The study diet employed here enabled us to investigate 
possible milk CLA effects independently of associated 
microbes or heat-sensitive ingredients as these compo-
nents were separated or denatured during pasteurization. 
In contrast, the milk lipid fraction was not affected by 
milk processing as no significant loss of CLA was ob-







16:0–18:2 PE 18 17 19
18:0–18:2 PE 5 4 8
20:4–18:2 PE 77 76 73
16:0–18:2 PC 62 54 60
18:0–18:2 PC 21 21 26
18:1–18:2 PC 17 25 14
 The lipid extracts of each group (n = 8) were pooled, evapo-
rated and redissolved and injected into the HPLC system. Lipid 
fractions containing linoleic acid residues were isolated and frag-
mented using IRMPD. Linoleic acid isomers containing fractions 
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served. Since direct administration of cow’s milk to mice 
is conflicting due to incompatibilities and insufficient up-
take by this species, Kanwar et al.  [19] suggested the in-
corporation of milk fat fractions into the mouse diet to 
overcome these problems. Our data indicate that this 
mode of application does not hamper the bioavailability 
of milk fat fractions as an increasing uptake of milk CLA 
over time was observed. Therefore, this mode of milk fat 
administration to mice seems to be an appropriate ap-
proach to prove the physiological impacts of lipids from 
natural sources in an experimental model.
 However, no allergopreventive effects of CLA-rich 
milk fat were observed in our experiments based on a 
model that avoided the use of alum as an adjuvant to fa-
cilitate the modification of sensitization and effector 
phase mechanisms  [20] . The lack of an allergoprotective 
effect is surprising, as it has previously been shown that 
members of the CLA family possess properties that allow 
them to modulate proinflammatory processes  [15, 35] . 
CLA are capable of interfering with the synthesis of bio-
active eicosanoid mediators such as PG, TX, and LT  [32] . 
The metabolism of these lipid mediators is primarily de-
termined by the availability of FAs in membrane phos-
pholipids  [36] . In particular, the phospholipid subtypes 
PC and PE are of main interest since these phospholipids 
are substrates for phospholipase A2 generating FFA  [28, 
29] . Enhanced consumption of CLA has been shown to 
increase the proportions of these PUFA in cell membrane 
phospholipids, partly at the expense of n–6 PUFA arachi-
donic acid  [37] . Additionally, CLA might reduce eico-
sanoid synthesis by inhibition of cyclooxygenase-2 and 
lipoxygenase  [38–40] . In particular, PGD 2 and LTB 4 are 
thought to be involved in the asthma pathogenesis, since 
the comparison of nonasthmatics and asthmatics has 
shown increased levels of these eicosanoids in the latter 
[as reviewed in  33, 41 ]. In our model, we examined this 
mechanistic pathway in detail. Though consumption of a 
CLA-enriched diet increased the CLA content in plasma 
and erythrocyte membranes, no changes in the composi-
tion of the respective phospholipids (PE and PC) was ob-
served. This observation might explain why, despite the 
increased CLA amount in plasma and erythrocytes, this 
uptake did not alter the content of the eicosanoids PGD 2 , 
PGE 2 , 6-keto-PGF 1a , and LTB 4 in the BAL fluid of mice. 
In contrast to our results, Whigham et al. [42] observed a 









































PBS/PBS + CLA-free diet
OVA/OVA + CLA-free diet
OVA/OVA + high-CLA diet
OVA/OVA + low-CLA diet
 Fig. 4. Milk CLA supplementation does not affect the eicosanoid pattern in BAL. PGD 2 , PGE 2 , 6-keto-PGF 1a , and 
LTB 4 were measured in BAL fluid using LC-MS/MS, 48 h after the last challenge. PGF2a, TXB2, and 5S- and 15S-
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parison to the basal release of eicosanoids in CLA-supple-
mented animals when respiratory organs were challenged 
with OVA ex vivo. Furthermore, Jaudszus et al.  [18] 
showed that dietary CLA supplementation of mice with a 
synthetic FA affects sensitization and is capable of reduc-
ing the release of the proinflammatory cytokine IL-5. Our 
experiments, applying CLA in a natural matrix revealed 
no decrease in T H2 cytokines in milk diet-fed animals. 
Moreover, consumption of a CLA-enriched diet did not 
attenuate any of the hallmarks of allergic airway inflam-
mation. These different findings could be explained by 
the fact that high-dosage supplementation with a pure 
synthetic product might be needed to effectively prevent 
the development of an asthmatic phenotype while exclu-
sive uptake of natural CLA from milk fails to reach the 
required threshold. Alternatively, it may be speculated 
that specific CLA, e.g. C9t11-CLA, are responsible for the 
mediation of protective effects  [15] . However, the uptake 
of this specific CLA did not significantly differ after con-
sumption of the two diets used in this model ( fig.  2 ). 
Though we demonstrated that farm milk contains sig-
nificantly higher amounts of CLA compared to dairy 
milk, this enrichment seems to be insufficient for a pro-
tective effect against experimental airway inflammation. 
Recent data from experimental studies underline this no-
tion by showing that additional supplementation of milk 
CLA diets with synthetic CLA might reveal concentra-
tions of CLA in the animals that provide protection 
against airway inflammation  [19, 43] .
 However, milk CLA may have protective effects in 
synergism with other ingredients of farm milk that do not 
survive pasteurization. Nevertheless, which milk fraction 
is responsible for allergoprotection remains uncertain. 
Therefore, further research is needed to answer the ques-
tion of whether the health benefits of unpasteurized farm 
milk can be attributed to a single milk component or to 
farm milk as a whole.
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